Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials

<i>Plasmodium</i> spp. malaria parasites in the blood stage draw energy from anaerobic glycolysis when multiplying in erythrocytes. They tap the ample glucose supply of the infected host using the erythrocyte glucose transporter 1, GLUT1, and a hexose transporter, HT, of the parasite’s p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cornelius Nerlich, Nathan H. Epalle, Philip Seick, Eric Beitz
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/bafceb0d7e8341a99b01aa4465180765
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bafceb0d7e8341a99b01aa4465180765
record_format dspace
spelling oai:doaj.org-article:bafceb0d7e8341a99b01aa44651807652021-11-25T18:40:04ZDiscovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials10.3390/ph141111911424-8247https://doaj.org/article/bafceb0d7e8341a99b01aa44651807652021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1191https://doaj.org/toc/1424-8247<i>Plasmodium</i> spp. malaria parasites in the blood stage draw energy from anaerobic glycolysis when multiplying in erythrocytes. They tap the ample glucose supply of the infected host using the erythrocyte glucose transporter 1, GLUT1, and a hexose transporter, HT, of the parasite’s plasma membrane. Per glucose molecule, two lactate anions and two protons are generated as waste that need to be released rapidly from the parasite to prevent blockage of the energy metabolism and acidification of the cytoplasm. Recently, the missing <i>Plasmodium</i> lactate/H<sup>+</sup> cotransporter was identified as a member of the exclusively microbial formate–nitrite transporter family, FNT. Screening of an antimalarial compound selection with unknown targets led to the discovery of specific and potent FNT-inhibitors, i.e., pentafluoro-3-hydroxy-pent-2-en-1-ones. Here, we summarize the discovery and further development of this novel class of antimalarials, their modes of binding and action, circumvention of a putative resistance mutation of the FNT target protein, and suitability for in vivo studies using animal malaria models.Cornelius NerlichNathan H. EpallePhilip SeickEric BeitzMDPI AGarticleformate–nitrite transporterlactate<i>Plasmodium</i>malariaantimalarialsMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1191, p 1191 (2021)
institution DOAJ
collection DOAJ
language EN
topic formate–nitrite transporter
lactate
<i>Plasmodium</i>
malaria
antimalarials
Medicine
R
Pharmacy and materia medica
RS1-441
spellingShingle formate–nitrite transporter
lactate
<i>Plasmodium</i>
malaria
antimalarials
Medicine
R
Pharmacy and materia medica
RS1-441
Cornelius Nerlich
Nathan H. Epalle
Philip Seick
Eric Beitz
Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials
description <i>Plasmodium</i> spp. malaria parasites in the blood stage draw energy from anaerobic glycolysis when multiplying in erythrocytes. They tap the ample glucose supply of the infected host using the erythrocyte glucose transporter 1, GLUT1, and a hexose transporter, HT, of the parasite’s plasma membrane. Per glucose molecule, two lactate anions and two protons are generated as waste that need to be released rapidly from the parasite to prevent blockage of the energy metabolism and acidification of the cytoplasm. Recently, the missing <i>Plasmodium</i> lactate/H<sup>+</sup> cotransporter was identified as a member of the exclusively microbial formate–nitrite transporter family, FNT. Screening of an antimalarial compound selection with unknown targets led to the discovery of specific and potent FNT-inhibitors, i.e., pentafluoro-3-hydroxy-pent-2-en-1-ones. Here, we summarize the discovery and further development of this novel class of antimalarials, their modes of binding and action, circumvention of a putative resistance mutation of the FNT target protein, and suitability for in vivo studies using animal malaria models.
format article
author Cornelius Nerlich
Nathan H. Epalle
Philip Seick
Eric Beitz
author_facet Cornelius Nerlich
Nathan H. Epalle
Philip Seick
Eric Beitz
author_sort Cornelius Nerlich
title Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials
title_short Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials
title_full Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials
title_fullStr Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials
title_full_unstemmed Discovery and Development of Inhibitors of the Plasmodial FNT-Type Lactate Transporter as Novel Antimalarials
title_sort discovery and development of inhibitors of the plasmodial fnt-type lactate transporter as novel antimalarials
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/bafceb0d7e8341a99b01aa4465180765
work_keys_str_mv AT corneliusnerlich discoveryanddevelopmentofinhibitorsoftheplasmodialfnttypelactatetransporterasnovelantimalarials
AT nathanhepalle discoveryanddevelopmentofinhibitorsoftheplasmodialfnttypelactatetransporterasnovelantimalarials
AT philipseick discoveryanddevelopmentofinhibitorsoftheplasmodialfnttypelactatetransporterasnovelantimalarials
AT ericbeitz discoveryanddevelopmentofinhibitorsoftheplasmodialfnttypelactatetransporterasnovelantimalarials
_version_ 1718410860457623552